(Q44486357)

3 December 2017

title

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations (English)

1 reference

3 December 2017

1 reference

1 reference

1 reference

Alan H B Wu

1

1 reference

3 December 2017

Ping Wang

2

1 reference

3 December 2017

Andrew Smith

3

1 reference

3 December 2017

Christine Haller

4

1 reference

3 December 2017

Katherine Drake

5

1 reference

3 December 2017

Mark Linder

6

1 reference

3 December 2017

Roland Valdes

7

1 reference

3 December 2017

publication date

1 February 2008

1 reference

3 December 2017

1 reference

3 December 2017

volume

9

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

169-178

1 reference

Risk of major hemorrhage for outpatients treated with warfarin

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Increased sensitivity to warfarin in elderly Hispanics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Population variation in VKORC1 haplotype structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

APOE genotype makes a small contribution to warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.169

21 January 2018

Identifiers

DOI

10.2217/14622416.9.2.169

1 reference

3 December 2017

1 reference